2021
Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness
Luykx J, Loef D, Lin B, van Diermen L, Nuninga J, van Exel E, Oudega M, Rhebergen D, Schouws S, van Eijndhoven P, Verwijk E, Schrijvers D, Birkenhager T, Ryan K, Arts B, van Bronswijk S, Kenis G, Schurgers G, Baune B, Arns M, van Dellen E, Somers M, Sommer I, Boks M, Gülöksüz S, McLoughlin D, Dols A, Rutten B. Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry 2021, 91: 531-539. PMID: 34955169, DOI: 10.1016/j.biopsych.2021.10.013.Peer-Reviewed Original ResearchConceptsMajor depressive episodeHamilton Depression Rating Scale scoresDepression Rating Scale scoresRating Scale scoresPolygenic risk scoresPRS-SCZECT outcomeElectroconvulsive therapyScale scoreSevere major depressive episodeUnipolar major depressive episodeMajor depressive disorderSecondary outcomesAntidepressant responseECT treatmentDepressive episodeSubgroup analysisECT effectivenessPsychotic featuresDepressive disorderTreatment responseMAIN OUTCOMEEffective treatmentRisk scoreTherapy effectiveness
2018
Evaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients.
Altınbaş K, Yeşilbaş D, İnce B, Cansız A, Sılan F, Özdemir Ö, Gülöksüz S. Evaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients. Turkish Journal Of Psychiatry 2018, 29: 73-78. PMID: 30215834, DOI: 10.5080/u20582.Peer-Reviewed Original ResearchConceptsMean ageLithium treatmentTreatment responseGSK-3βBipolar disorder type IBipolar disorder patientsLack of evidenceClinical predictorsHospital recordsTreatment adherenceTreatment optionsDisease onsetFirst episodeReal-time PCRIndividualized treatmentPharmacogenomic findingsBlood samplesDisorder patientsSide effectsAG genotypeClinical practiceScale scoreBipolar disorderPatientsSample cohort